Sat, Sep 20, 2014, 12:56 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wildbiftek wildbiftek Oct 18, 2013 9:34 AM Flag

    Ariad terminates Iclusig trial

    I'm guessing that if 30 or 15 mg were an option, they would have opted for it instead of halting the trial.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Reading on clinical trial dot gov, it looks like 45 mg was the only dosing option for EPIC, a trial in first line CML. Increasing the Imatinib dosing was permitted. Scuttling the trial as it stood was probably necessary, It looks like lower doses of ponatinib weren't an option.

      • 1 Reply to wildbiftek
      • Lower doses weren't an option for that trial Starting over may not be an option either as it may prove too expensive. Meanwhile the buzzards are circling. They have over $300mm net in the kitty but they are going to need it just to survive. I took my medicine this morning in the pre-market. Pity...the drug actually does work and there is a pretty obvious pathway to utilizing it appropriately, i.e. reduce the dose and screen the patient population for previous stroke and cardiac events. That's where they will likely end up but it's going to be very expensive and time consuming getting there.

 
EXEL
1.70-0.02(-1.16%)Sep 19 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TC PipeLines, LP
NYSEFri, Sep 19, 2014 4:00 PM EDT
Concur Technologies, Inc.
NasdaqGSFri, Sep 19, 2014 4:00 PM EDT